Autologous Activated Platelet-Rich Plasma Therapy for Pregnant COVID-19 Patients: A Case Series

Authors

  • Karina Karina Faculty of Medicine, Universitas Pembangunan Nasional Veteran Jakarta, Jakarta, Indonesia
  • Louis Martin Christoffel Koja Regional Public Hospital, Jakarta, Indonesia
  • Rita Novariani Koja Regional Public Hospital, Jakarta, Indonesia
  • Imam Rosadi Department of Biology, Faculty of Mathematics and Natural Sciences, Mulawarman University, Samarinda, Indonesia
  • Siti Rosidah Koja Regional Public Hospital, Jakarta, Indonesia
  • Siti Sobariah HayandraLab, Hayandra Peduli Foundation, Jakarta, Indonesia
  • Grady Krisandi Faculty of Medicine, University of Indonesia, Jakarta, Indonesia
  • Novy Fatkhurohman Koja Regional Public Hospital, Jakarta, Indonesia
  • Nurlaela Puspitaningrum Koja Regional Public Hospital, Jakarta, Indonesia
  • Yuli Hertati Koja Regional Public Hospital, Jakarta, Indonesia
  • Irsyah Afini HayandraLab, Hayandra Peduli Foundation, Jakarta, Indonesia
  • Difky Ernanda HayandraLab, Hayandra Peduli Foundation, Jakarta, Indonesia
  • Tias Widyastuti HayandraLab, Hayandra Peduli Foundation, Jakarta, Indonesia
  • Alfida Zakiyah HayandraLab, Hayandra Peduli Foundation, Jakarta, Indonesia
  • Noor Aini HayandraLab, Hayandra Peduli Foundation, Jakarta, Indonesia

Keywords:

coronavirus disease 2019, pregnancy, platelet-rich plasma

Abstract

As pregnant women with COVID-19 have higher mortality rates and as more of them are getting infected, it is crucial to find a more efficacious and safer therapy. Among the various therapies available, intravenous autologous activated platelet-rich plasma (aaPRP) is a potential candidate due to its well-known anti-inflammatory effect and autologous property. To our knowledge as of the writing of this manuscript, this is the first report of intravenous autologous activated platelet-rich plasma therapy in pregnant COVID-19 patients. We reported a case series of pregnant COVID-19 patients, in which two had severe to critical symptoms (age 34 and 26) and two had mild to moderate symptoms (age 41 and 25). The use of intravenous autologous activated platelet-rich plasma was able to ameliorate the hyperinflammatory and hypercoagulability state the patients were in, without any adverse events observed.

Downloads

Published

2022-03-06